Synthetic Biologics Inc., a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, has appointed Raymond Stapleton as senior vice president, manufacturing. Dr. Stapleton will lead the manufacturing team as the company begins to prepare for late-stage clinical trials for its irritable bowel syndrome with constipation (IBS-C) and C. difficile programs, and continues to move its monoclonal antibody (mAb) program forward to add...